Trials / Completed
CompletedNCT00126412
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
An Open-Label, Multicentre, Phase 3 Scintigraphy Study Assessing 123I-mIBG Uptake in Subjects Being Evaluated for Phaeochromocytoma or Neuroblastoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- GE Healthcare · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 123I-mIBG (meta-iodobenzylguanidine) |
Timeline
- Start date
- 2005-08-02
- Primary completion
- 2006-09-27
- Completion
- 2006-09-27
- First posted
- 2005-08-04
- Last updated
- 2019-05-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00126412. Inclusion in this directory is not an endorsement.